FDA Approves Libtayo for High-Risk Cutaneous Squamous Cell Carcinoma After Surgery

Drug Approvals /

The FDA has approved Libtayo (cemiplimab-rwlc) for adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. Approval was based on the phase 3 C-POST trial of 415 patients, which showed significantly improved disease-free survival with Libtayo versus placebo. Median disease-free survival was not reached in […]

FDA Approves Libtayo for High-Risk Cutaneous Squamous Cell Carcinoma After Surgery Read More »

WTX-124 Fast-Tracked by FDA for Melanoma After Immunotherapy Failure

Research Advances /

The FDA has granted fast track designation to WTX-124, a conditionally activated interleukin-2 (IL-2) therapy, for patients with locally advanced or metastatic cutaneous melanoma after standard immunotherapy. WTX-124, designed to deliver IL-2 selectively to tumors and reduce systemic toxicity, is being studied as monotherapy and in combination with pembrolizumab in a phase 1/1b trial for

WTX-124 Fast-Tracked by FDA for Melanoma After Immunotherapy Failure Read More »

IDE397 Plus Trodelvy Shows Strong Early Efficacy in MTAP-Deleted Urothelial Cancer

Treatment /

A phase 1/2 trial evaluating IDE397, a MAT2A inhibitor, combined with sacituzumab govitecan-hziy (Trodelvy) shows encouraging activity in late-line MTAP-deletion urothelial cancer. Two expansion cohorts were assessed. Dose Level 1 (IDE397 15 mg + Trodelvy 10 mg/kg, n=9) achieved a 33% objective response rate (ORR) and 100% disease control rate (DCR). Dose Level 2 (IDE397

IDE397 Plus Trodelvy Shows Strong Early Efficacy in MTAP-Deleted Urothelial Cancer Read More »

Dostarlimab Boosts Survival in Advanced Endometrial Cancer

Treatment /

Endometrial cancer, the second most common gynecologic malignancy, is typically treated with carboplatin and paclitaxel, but outcomes remain poor. The Phase 3 RUBY trial evaluated adding the anti–PD-1 drug dostarlimab to this regimen in 494 patients with newly diagnosed advanced or recurrent disease. Dostarlimab significantly improved results: in patients with mismatch repair–deficient or MSI-high tumors,

Dostarlimab Boosts Survival in Advanced Endometrial Cancer Read More »

GRAPE: An AI-Powered Revolution in Opportunistic Gastric Cancer Screening

Diagnostics /

Gastric cancer (GC) is a leading cause of cancer death globally. Early diagnosis is critical, as the five-year survival rate drops from up to 99% for early-stage GC (EGC) to under 30% for advanced stages. While standard endoscopy screening has lowered mortality in some countries, it is generally too expensive and invasive for large-scale public

GRAPE: An AI-Powered Revolution in Opportunistic Gastric Cancer Screening Read More »

Tumor Bacteria Produce Molecule That Enhances Chemotherapy and Fights Cancer

Molecular Oncology /

International scientists discovered that bacteria living in tumors produce a molecule called 2-methylisocitrate (2-MiCit) that can fight cancer and enhance chemotherapy effectiveness. Through screening over 1,100 conditions using C. elegans worms, scientists found that E. coli bacteria produce 2-MiCit, which improves the effectiveness of the chemotherapy drug 5-fluorouracil (5-FU). The molecule works by inhibiting a

Tumor Bacteria Produce Molecule That Enhances Chemotherapy and Fights Cancer Read More »

Blocking EZH2 Enzyme Shows Promise in Stopping Triple-Negative Breast Cancer Spread

Research Advances /

A new Weill Cornell Medicine study suggests a promising approach to stop the spread of Triple-Negative Breast Cancer (TNBC), one of the most aggressive cancer forms. Researchers found that the enzyme EZH2 drives TNBC cells to divide abnormally, leading to chromosomal instability and enabling them to metastasize (spread to distant organs). The study, published in Cancer Discovery, found that drugs

Blocking EZH2 Enzyme Shows Promise in Stopping Triple-Negative Breast Cancer Spread Read More »

Glioblastoma Erodes Skull and Manipulates Bone Marrow to Accelerate Tumor Growth

Research Advances /

A study from Montefiore Einstein Comprehensive Cancer Center in Nature Neuroscience reveals that glioblastoma (GBM) is not just a local brain tumor but a systemic disease affecting the skull and immune system. GBM causes skull thinning, enlarging channels between the skull marrow and brain. This remodeling shifts immune balance—doubling pro-inflammatory neutrophils and nearly eliminating B cells—allowing

Glioblastoma Erodes Skull and Manipulates Bone Marrow to Accelerate Tumor Growth Read More »

Detecting Cancer Three Years Earlier with Plasma Cell-Free DNA

Diagnostics /

A study used non-interventional, prospectively collected plasma from the ARIC cohort to assess a multi-cancer early detection (MCED) strategy using circulating tumor DNA (ctDNA). This unique design allowed for the observation of cancer’s natural progression. In Phase I, analyzing “Early plasma samples” (collected ≤6 months before diagnosis) from 26 cancer cases and 26 controls, ctDNA

Detecting Cancer Three Years Earlier with Plasma Cell-Free DNA Read More »

Advancing Gynecologic Oncology: The Role of AI in Diagnostics and Treatment

Technology Innovation /

AI is revolutionizing gynecologic cancer care (cervical, ovarian, endometrial) by improving early detection, diagnosis, and treatment planning. Machine learning (ML) and deep learning (DL) enhance screening accuracy, automate workflows, and integrate complex clinical data, addressing gaps in traditional methods and increasing efficiency in EHR management and clinical trial enrollment. In screening, AI enables automated Pap

Advancing Gynecologic Oncology: The Role of AI in Diagnostics and Treatment Read More »